论文部分内容阅读
目的:评价胺碘酮和厄贝沙坦联合治疗阵发性心房颤动维持窦性心律的长期疗效。方法:将110例阵发性房颤患者随机分为胺碘酮组(Ⅰ组,n=55)、胺碘酮+厄贝沙坦组(Ⅱ组,n=55),治疗随访时间为2年,研究的一级终点为房颤复发。比较两组治疗后的窦性心律维持率以及治疗前、治疗后6、12、18和24个月的左心房内径。结果:治疗12个月后,I组左心房内径大于Ⅱ组(P<0.05)。试验终点时,I组的窦性心律维持率为58.18%(32/55),Ⅱ组为78.18%(43/55)。持续性窦性心动过缓和QT间期≥0.5s的发生率两组间差异无统计学意义。结论:胺碘酮联合厄贝沙坦,治疗阵发性房颤维持窦性心律优于单用胺碘酮,并能抑制左心房的扩大。
OBJECTIVE: To evaluate the long-term efficacy of amiodarone and irbesartan in the treatment of paroxysmal atrial fibrillation to maintain sinus rhythm. Methods: 110 patients with paroxysmal atrial fibrillation were randomly divided into amiodarone group (n = 55), amiodarone + irbesartan group (n = 55), and the follow-up time was 2 Year, the primary endpoint of the study was recurrence of atrial fibrillation. The maintenance rate of sinus rhythm after treatment and the left atrium diameter at 6, 12, 18 and 24 months after treatment were compared between the two groups. Results: After 12 months of treatment, the diameter of the left atrium in group I was larger than that in group II (P <0.05). At the end of the trial, the maintenance rate of sinus rhythm was 58.18% (32/55) in group I and 78.18% (43/55) in group II. Persistent sinus bradycardia and QT interval ≥ 0.5s incidence between the two groups showed no significant difference. Conclusion: Amiodarone combined with irbesartan in patients with paroxysmal atrial fibrillation to maintain sinus rhythm better than single amiodarone, and can inhibit the expansion of the left atrium.